Overall verdict
Neutral
6.0/10
1-year performance
-12.04%
Score breakdown
Down 12.0% over 1 year, 23% of the 52-week range.
Strongest: Profitability 8.4/10. Weakest: Growth 2.1/10.
19 analysts.
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands.
In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
Sector
Consumer Staples
Industry
Household Products
Primary listing
Lse
United Kingdom
CEO
Kristoffer Licht
Founded
1819
Employees
—
Revenue / employee
—
Next earnings
October 23, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
65.23 GBP
52-week low
44.21 GBP
1-year performance
-12.04%
Declining
Year-to-date performance
-17.08%
Declining
Drawdown
-24.80%
Marked drawdown
Position in the 52-week range
23% of range
Range: 82.60 GBP - 94.98 GBP (comparables only)
The price implies growth of 5.25% per year; the company grows at 22.95%.
Gross margin 59.5%, net margin 21.2%, ROIC 22.4%, ROE 48.2%.
Net margin
21.19%
Exceptional
Sector 8.17%|S&P 12.97%
Gross margin
59.48%
Exceptional
Return on equity (ROE)
48.22%
Exceptional
Sector 11.27%|S&P 16.52%
Return on invested capital (ROIC)
22.36%
Exceptional
Free cash flow margin (FCF)
11.35%
Fair
Profit-to-cash conversion (FCF conversion)
0.54x
Fair
Margin stability
14.9 pts
Very uneven
Revenue to net income
Growth
2.1/10Revenue down 8.2% over 1 year, 0.3% a year over 5, EPS 22.9% a year over 5.
Revenue (trailing 12 months)
13.6Md GBP
Revenue growth (1y)
-8.20%
Declining
Revenue growth (3y)
-1.72%
Declining
EPS growth (1y)
-30.90%
Declining
EPS CAGR (5y)
22.95%
Exceptional
EPS revisions (3 months)
0.73%
Revised up
Valuation
7.8/10P/E 11.1x, forward P/E 16.9x, EV/EBITDA 8.5x, PEG 0.48.
P/E (TTM)
11.1x
Cheap
Sector 18.9x|S&P 23.0x
Forward P/E
16.9x
Fair
EV / EBITDA
8.5x
Fair
Sector 10.1x|S&P 14.5x
PEG
0.48
Growth unpriced
Sector 0.79|S&P 0.86
Fair value (reverse DCF)
88.79 GBP
Deeply undervalued
Market cap
31.5Md GBP
Financial strength
5.0/10Cash covers 8.6% of the debt, net debt/EBITDA 1.7x.
Net debt / EBITDA
1.7x
Tight
Gearing (net debt / equity)
162.75%
Stretched
Cash
864M GBP
Cash / market cap
2.74%
Stretched
Cash / total debt
8.64%
Stretched
Net debt
9.1Md GBP
Equity
5.6Md GBP
Closed daily candles, 2 years
Last close on September 24, 2026: 49.23 GBP
- MM2050.63
- MM5051.11
- MM20053.72
- RSI 1441.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.03%
200-day average slope, 3 months
-5.23%
50-day average slope, 1 month
+1.31%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.62 % per day
Volatility change
+0.24%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.90 (9) | 3.35 (19) | 13 062 (18) | 3 617 (18) | 1 805 (6) |
| 2027 | 3.40 (9) | 3.60 (19) | 13 422 (18) | 3 817 (18) | 2 122 (6) |
Amounts in millions of GBP, EPS in GBP per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 34 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 8113 | 6.1 | 6.2 | 11.1Md USD | 25.6x | 6.7 % | 6.9 % | 8.1 % | -1.9x | 6.0 % | -2.5 % | ||
| 2 | RKT | 6.0 | 6.0 | 41.7Md USD | 11.1x | 21.2 % | -8.2 % | 22.4 % | 1.7x | 4.9 % | -12.0 % | ||
| 3 | CHD | 5.7 | 5.3 | 22.8Md USD | 30.9x | 12.0 % | 1.6 % | 11.1 % | 1.5x | 4.9 % | 9.7 % | ||
| 4 | HEN3 | 5.7 | 5.9 | 32.6Md USD | 15.8x | 9.4 % | — | 8.3 % | 0.2x | 7.1 % | 6.9 % | ||
| 5 | CL | 5.6 | 5.0 | 68.5Md USD | 34.0x | 9.7 % | 4.9 % | 25.6 % | 1.5x | 5.6 % | 6.9 % | ||
| 6 | PG | 5.5 | 5.2 | 342Md USD | 22.3x | 18.4 % | 1.5 % | 20.7 % | 1.0x | 4.4 % | -4.2 % | ||
| 7 | KMB | 5.4 | 5.1 | 32.5Md USD | 16.6x | 10.2 % | 0.6 % | 21.1 % | 2.1x | 5.6 % | -21.1 % | ||
| 8 | ESSITY B | 5.2 | 5.2 | 17.9Md USD | 14.8x | 8.8 % | 2.6 % | 10.2 % | 1.1x | 6.2 % | 8.3 % | ||
| 9 | CLX | 4.3 | 4.3 | 10.2Md USD | 17.4x | 8.7 % | -2.0 % | 15.4 % | 4.8x | 4.0 % | -32.1 % |
